TSGF与直肠癌新辅助放化疗敏感性相关性研究.docVIP

TSGF与直肠癌新辅助放化疗敏感性相关性研究 　　[摘要] 目的 探讨TSGF在直肠癌新辅助治疗疗效评价中的价值。方法 整群选取2013年6月―2015年7月就诊于该院的55例直肠癌患者，行新辅助放化疗，于新辅助治疗前、治疗后1周及6周分别行TSGF、CEA检测，新辅助治疗前、治疗后6周分别行盆腔MRI检查，观察新辅助放疗前后TSGF、CEA、直肠肿瘤大小的变化情况。结果 TSGF在新辅助治疗前为（140.79±50.98）U/ml，治疗结束后1周为（106.88±37.67）U/ml，结束后6周为（93.08±38.72） U/ml，下降明显，差异有统计学意义（P0.01）；新辅助治疗前肿瘤大小为（9.87±1.07）cm，治疗后大小为（6.46±1.91）cm，差异有统计学意义（P0.01）；肿瘤大小的变化与TSGF呈正相关（r=0.784，P0.01），与CEA呈负相关（r=-0.085，P=0.053）。结论 TSGF可作为直肠癌新辅助治疗疗效的评价指标之一。 　　[关键词] TSGF；直肠肿瘤；新辅助治疗；敏感性 　　[中图分类号] R5 [文献标识码] A [文章编号] 1674-0742（2016）04（c）-0030-03 　　[Abstract] Objective To discuss the value of TSGF in the curative effect evaluation of the neoadjuvant therapy for rectal cancer. Methods 55 cases of patients with rectal cancer diagnosed in our hospital from June 2013 to July 2015 were selected and were given the neoadjuvant chemoradiotherapy， and were given the TSGF detection and CEA detection respectively before the neoadjuvant therapy and at 1-week and 6-week after treatment and were given the pelvic MRI examination respectively before the neoadjuvant therapy and at 6-week after treatment， and the changes of TSGF， CEA and rectal tumor size before and after the neoadjuvant chemoradiotherapy were observed. Results TSGF was respectively（140.79±50.98） U/ml， （106.88±37.67） U/ml and（93.08±38.72） U/ml before the neoadjuvant therapy and at 1-week and 6-week after treatment， and the decreases were obvious and there were obvious differences（P0.01）； there was an obvious difference in the tumor size before and after the neoadjuvant therapy， [（9.87±1.07） cm vs （6.46±1.91） cm]，（P0.01）； and the change of the tumor size was correlated with the TSGF，（r=0.784， P0.01）， and that was negative correlation of CEA，（r=0.784，P0.01）. Conclusion TSGF can be used as one of the curative effect evaluation indexes in the neoadjuvant chemoradiotherapy. 　　[Key words] TSGF； Rectal tumor； Neoadjuvant therapy； Sensitivity 　　直肠癌是常见的消化系统恶性肿瘤之一，手术是目前直肠癌的首选治疗方法，但是，手术治疗已无法取得更好的治疗效果。近年来，随着新辅助放化疗（指恶性肿瘤手术治疗前应用的放疗和化疗）在中低位直肠癌治疗中的应用